← feed

Is NCT02286219 results overdue?

Yes — results are overdue. Primary completion was 2017-06-08; the FDAAA-801 reporting deadline (2018-06-08) passed 2935 days ago and no results are posted on ClinicalTrials.gov.

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

NCT IDNCT02286219 ↗
SponsorBristol-Myers Squibb (INDUSTRY)
Public issuerBRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-08 (ACTUAL)
Reporting deadline2018-06-08 (completion + 365d)
Days overdue2935
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 5a3eef244f35d25d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02286219. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →